Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LNC Technology
    • LNC Platform
    • MAT2203
    • MAT2501
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 04, 2020 7:00am EST

Matinas BioPharma Appoints James A. Underberg, M.D. to its MAT9001 Scientific Advisory Board

Feb 24, 2020 4:15pm EST

Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Operational and Financial Results on March 9, 2020

Feb 19, 2020 7:00am EST

Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

Jan 14, 2020 11:21am EST

Matinas BioPharma Announces Closing of Public Offering of Common Stock

Jan 10, 2020 8:00am EST

Matinas BioPharma Announces Pricing of Public Offering of Common Stock

Jan 09, 2020 4:05pm EST

Matinas BioPharma Announces Proposed Public Offering of Common Stock

Dec 12, 2019 7:00am EST

Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform

Nov 18, 2019 7:30am EST

Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

Nov 13, 2019 6:30am EST

Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 06, 2019 7:30am EST

Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, 2019

RSS
  • Prev
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...24
    Next
    Matinas BioPharma Holdings, Inc.

    Science

    • LNC PLATFORM
    • MAT2203
    • MAT2501

    Investors

    • COMPANY PROFILE
    • STOCK DATA
    • ANALYST COVERAGE
    • GOVERNANCE
    • PRESS RELEASES
    • EVENTS
    • PRESENTATIONS
    • SEC FILINGS

    Company

    • OVERVIEW
    • OUR TEAM
    • NEWS
    • CAREERS
    • CONTACT US

    Register for updates

    Follow Us

    LinkedIn facebook twitter
    © 2023 Matinas BioPharma Holdings, Inc. All Rights Reserved.